TCGA-CV-7414-01A-11R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.003196347
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.330
- HEDGEHOG_SIGNALING+0.320
- PANCREAS_BETA_CELLS+0.180
- MYOGENESIS+0.170
- OXIDATIVE_PHOSPHORYLATION+0.170
- PEROXISOME+0.150
- WNT_BETA_CATENIN_SIGNALING+0.150
- ESTROGEN_RESPONSE_EARLY+0.130
- ESTROGEN_RESPONSE_LATE+0.100
- PI3K_AKT_MTOR_SIGNALING+0.080
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.480
- IL6_JAK_STAT3_SIGNALING-0.420
- INFLAMMATORY_RESPONSE-0.410
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_GAMMA_RESPONSE-0.330
- MYC_TARGETS_V2-0.320
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- COMPLEMENT-0.270
- APOPTOSIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1320873 | GTEX | — | 0.828 |
| 2 | SRR600445 | GTEX | — | 0.816 |
| 3 | SRR807591 | GTEX | — | 0.804 |
| 4 | SRR1387809 | GTEX | — | 0.797 |
| 5 | SRR1498640 | GTEX | — | 0.790 |
| 6 | SRR1310008 | GTEX | — | 0.789 |
| 7 | SRR602169 | GTEX | — | 0.789 |
| 8 | SRR1356619 | GTEX | — | 0.789 |
| 9 | SRR1375308 | GTEX | — | 0.786 |
| 10 | SRR1332796 | GTEX | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.010 | Inavolisib | — uncovered |